Since establishing its mRNA platform in 2022, Yaohai Bio-Pharma has supported over 800 RNA projects for universities, research institutes, and biotech companies. Built on expertise in plasmid DNA production, IVT process development, purification, LNP formulation, and analytical testing, our integrated platform supports mRNA programs from early development to GMP manufacturing, helping global partners accelerate timelines with reliable CMC support.
Built on over 10 years of experience in the mRNA field and fully integrated mRNACRDMO capabilities, Yaohai Bio-Pharma proudly offers the “RNASUP” platform. Our end-to-end mRNA services cover plasmid preparation, mRNA synthesis and purification, LNP encapsulation, GMP manufacturing, and regulatory support.
Our end-to-end mRNA CRDMO platform supports projects from early-stage R&D (mg scale) to commercial-scale production (tens of grams), while meeting EMA and FDA GMP requirements.
Yaohai Bio-Pharma has established robust and mature platforms for plasmid production, mRNA synthesis, and LNP formulation, providing end-to-end support for global clients across key development stages, from early R&D and clinical-stage process development to GMP manufacturing, analytical testing, drug product fill-finish, and regulatory submission support.
Yaohai Bio-Pharma delivers tailored solutions for global clients, meeting diverse project requirements with excellence and efficiency.
Proven track record of over 100 successful projects, spanning preclinical studies and Phase I/II/III clinical trials, including US–China dual submissions and Australian regulatory filings.
A robust GMP-aligned quality system with standardized SOPs, fully compliant with global regulatory guidelines across the entire product lifecycle.
Powered by industry-leading scientists and cross-functional experts, our team delivers CRDMO projects with speed, precision, and deep technical insight.
